09:02 AM EDT, 09/15/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Monday that it has secured a $17 million contract modification from a research center within the US Department of Health and Human Services, or HHS, to supply its Tembexa smallpox treatment.
The company said it received the contract modification from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the HHS.
Emergent said the latest contract modification is part of the company's existing 10-year contract.
Shares of the company were up 2.3% in recent Monday premarket activity.